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1888 wileyonlinelibrary.com/journal/bcpAims: Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential
application in a wide‐variety of contexts; however, its effective dose in different
disease states remains unclear. This review aimed to investigate what doses have
been applied in clinical populations, in order to understand the active range of CBD
in a variety of medical contexts.
Methods: Publications involving administration of CBD alone were collected by
searching PubMed, EMBASE and ClinicalTrials.gov.
Results: A total of 1038 articles were retrieved, of which 35 studies met inclusion
criteria covering 13 medical contexts. Twenty‐three studies reported a significant
improvement in primary outcomes (e.g. psychotic symptoms, anxiety, seizures), with
doses ranging between <1 and 50 mg/kg/d. Plasma concentrations were not pro-
vided in any publication. CBD was reported as well tolerated and epilepsy was the
most frequently studied medical condition, with all 11 studies demonstrating positive
effects of CBD on reducing seizure frequency or severity (average 15 mg/kg/d within
randomised controlled trials). There was no signal of positive activity of CBD in small
randomised controlled trials (range n = 6–62) assessing diabetes, Crohn's disease,
ocular hypertension, fatty liver disease or chronic pain. However, low doses (average
2.4 mg/kg/d) were used in these studies.
Conclusion: This review highlights that CBD has a potential wide range of activity
in several pathologies. Pharmacokinetic studies as well as conclusive phase III trials to
elucidate effective plasma concentrations within medical contexts are severely lack-
ing and highly encouraged.
KEYWORDS
cannabidiol, cannabinoid, dose, dosing, therapeutics1 | INTRODUCTION
Cannabidiol (CBD) is a non‐intoxicating major constituent of the
Cannabis sativa plant that has been increasing in interest due to its- - - - - - - - - - - - - - - - - - - - - - - - - -
Creative Commons Attribution Li
armacology published by John Wipotentially diverse range of therapeutic properties and its favourable
safety and tolerability profile.1 Side effects are generally mild and
infrequent, such as sleepiness, diarrhoea or increased temperature.
It is also reported that clinically significant drug‐interactions pose a- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cense, which permits use, distribution and reproduction in any medium, provided
ley & Sons Ltd on behalf of British Pharmacological Society.
Br J Clin Pharmacol. 2019;85:1888–1900.
What is already known about this subject
• Due to its favourable toxicity and side effect profile,
cannabidiol is under increasing investigation in the
commercial and medical industry to treat many clinical
indications.
What this study adds
• This study identifies the wide active dosing range of
cannabidiol (<1 to 50 mg/kg/d) within a variety of
medical conditions including epilepsy, anxiety and graft‐
vs‐host disease.
• This review indicates that studies that used higher doses
tended to have better therapeutic outcomes compared to
lower doses overall.
• This study identifies a strong existing need for dose‐
ranging clinical studies to be conducted in which plasma
concentrations can provide a better indication of the
therapeutic range of cannabidiol.
MILLAR ET AL. 1889low risk.2 There is no evidence for dependency or abuse potential
with CBD use, as concluded by the World Health Organisation Expert
Committee on Drug Dependence.1 The purported effects of CBD
include analgesic, anti‐inflammatory, antioxidant, anxiolytic, anticon-
vulsant and cytotoxic effects, which are mediated through signalling
mechanisms including the cannabinoid receptor 1 (weak agonist),
the cannabinoid receptor 2 (inverse agonist), the serotonin 1a
receptor (5‐HT1A), G protein‐coupled receptor 55 (GPR55), G
protein‐coupled receptor 18 (GPR18) and the transient receptor
potential cation channel subfamily V member 1 (TRPV1) receptors,
amongst others.3
Clinically, CBD is being investigated in multiple disease states
including neurodegeneration, anxiety disorder, orphan childhood
diseases with a prevalence of <5 in 10 000 individuals (e.g. tuberous
sclerosis complex) and addiction (ongoing trials in cannabis and
cocaine craving).4-6 Epidiolex has recently become the first Food and
Drug Administration‐approved CBD medicine, indicated for use in
Lennox–Gastaut or Dravet syndrome (childhood epilepsy) by oral
administration. Sativex is an oromucosal spray containing both CBD
and δ‐9‐tetrahydrocannibinol, which is licenced in the EU and Canada
for the treatment of multiple sclerosis associated spasticity. At the
time of writing, there are 49 clinical trials registered on clinicaltrials.
gov investigating CBD alone (either not yet recruiting, recruiting or
active) and there have been at least a further 100 clinical trials
previously registered containing CBD, indicating a significant clinical
interest with an ongoing need to ensure that human volunteers
engaged in these trials are given doses that are optimised for efficacy
and safety. Surprisingly, none of the 49 currently registered trials have
explicitly included a study design to investigate the dose‐ranging
efficacy of CBD.
Hemp‐derived CBD is commercially available and is currently used
as a health and food supplement commonly for anxiety and pain
relief. This market represents a flourishing industry expected to rise
financially and globally.7 However, the blurred lines between CBD
as a licensed medicine and CBD as an over‐the‐counter remedy
contribute to the overall lack of understanding of what dose of
CBD may be considered therapeutic. This is further hampered by
the lack of standardisation in over‐the‐counter CBD products and
their unregulated labelled doses.
Despite the prevalence of CBD use and current hype, guidance
on dose recommendations has not advanced and is not clear, addi-
tionally hampered by the striking lack of accessible pharmacokinetic
and bioavailability data of CBD in humans.8 No published study to
date has reported the absolute oral bioavailability of CBD in
humans.8 Limited dose‐determination studies have left a paucity in
data surrounding desired plasma concentrations to achieve minimum
effective doses. Additionally, the lack of information on the role of
different formulations and routes of administration on absorption
are also apparent. The aim of this review was to comprehensively
collate all published data relating to CBD administration in clinical
populations to describe the range of CBD doses assessed across
different pathological states.2 | METHODS
2.1 | Search strategy
The systematic review was carried out in accordance with PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta‐
Analyses) guidelines. A systematic search of PubMed, EMBASE
(including MEDLINE) and clinicaltrials.gov was conducted to retrieve
all articles reporting CBD administration in clinical populations using
‘CBD or Cannabidiol’ as search terms. Searches were restricted to
‘humans’ and ‘clinical trials and case reports’ in PubMed and EMBASE,
with no restrictions on clinicaltrials.gov. The searches were carried out
by 8 August 2018 by 2 independent researchers.2.2 | Eligibility criteria
The titles and abstracts of retrieved studies were examined by 2
independent researchers, and inappropriate articles were rejected.
Inclusion criteria were as follows: an original, peer‐reviewed published
paper that involved administration of CBD to a clinical population, or
reported on clinicaltrials.gov, and included an outcome measurement
to assess the efficacy of CBD i.e. improvement in disease. Exclusion
criteria were: administration in healthy participants only; CBD
administered in combination with other cannabinoids such as with δ‐
9‐tetrahydrocannibinol or as whole cannabis extracts; article not in
English; no stated concentration of CBD used; or no statistical results
reported. The reference lists of included studies were hand‐searched
for additional relevant studies.
1890 MILLAR ET AL.2.3 | Data acquisition and analysis
The included articles were analysed, and the following data extracted:
sample size, clinical population/medical context; study design and
length; administration route of CBD; source of CBD; dose of CBD;
side effects; and primary outcome results. All data entry was checked
by an additional independent researcher. Risk of bias of the 15
randomised controlled trials was assessed using the 2011 Cochrane
Collaboration's tool for assessing risk of bias.
As this review included studies of participants of all ages (from
infants to adults), dosing is reported in mg/kg of body weight to
allow for comparison. Where not available as mg/kg (24 studies),
dose was converted for adults using an average adult body weight
of 62 kg.9 In only 1 publication, a case report on a child, an average
child weight of 40 kg had to be used to convert reported mg/d dose
into mg/kg/d.10
A positive effect of CBD was determined by the presence of a sig-
nificant improvement in primary end points(s) or outcomes reported
compared to placebo or baseline. A lack of positive effect was deter-
mined if no significant improvements were reported. Mixed findings
were reported for example in case reports wherein some patients
improved, others did not, or where a primary outcome was not speci-
fied (exploratory study) and in which some endpoints improved while
others worsened (1 study) or remained unchanged.3 | RESULTS
The initial search yielded 1038 records, from which 896 abstracts
were reviewed, and 35 articles were included in the final analysis,
comprising a total number of 1223 participants. A flow chart of arti-
cle retrieval and selection is presented in Figure 1. Fifteen studies
were randomised controlled trials (RCTs), 8 were clinical trials but
not both randomised and controlled in design (for example open‐label
trials), and 12 articles were case reports/series. A description of each
study is presented in tables 1–3 according to study design. Results of
the risk of bias assessment of the RCTs are presented in Figure 2. A
component of blinding was included in 74% of the RCTs . No study
was reported with a high risk of selection bias, detection bias, or
reporting bias. Overall, most information was from studies at low risk
of bias. No study reported plasma concentrations of CBD. All studies
reported oral administration of CBD, either as an oral solution
(n = 11), capsules (n = 13), spray/sublingual (n = 4), or orally but
unspecified (n = 6).
Of the 15 RCTs, the range of doses investigated varied from
<1 mg/kg up to 20 mg/kg per day (average 9 mg/kg/d).11-19,21-25
Seven RCTs reported CBD efficacy (average dose 14 mg/kg/
d),11-13,16,19,20,24 7 studies describe neutral effects of CBD (average
dose 5 mg/kg/d)14,15,17,21-23,25 and 1 study showed both positive
and negative outcomes.18 In the remaining 8 clinical trials of variousFIGURE 1 Flow chart of study retrieval and
selection
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FIGURE 2 Risk of bias summary of the randomised controlled trials
included in the systematic review. Green indicates low‐risk bias, red
indicates high‐risk bias, and yellow indicates intermediate or unclear
risk
1896 MILLAR ET AL.study design, 7 studies reported CBD positively (average dosing
23 mg/kg/d)5,26-29,31,32 and 1 study was neutral (8 mg/kg/d).30
Within the 12 case studies and case series, 9 described positive
effects of CBD (average dosing 16 mg/kg/d),10,33-38,40,43 2 were
neutral (average dosing 21 mg/kg/d)39,41 and 1 study described
mixed results (3 mg/kg/d).42
Epilepsy was the most frequently studied medical condition, with all
11 studies describing beneficial effects of CBD in reducing the severity
or frequency of seizures.12,13,16,24,26-28,33-36 Within the 4 conducted
RCTs (n = 531), an average dosing of 15 mg/kg/d was used where
CBD was administered successfully as an add‐on therapy to usual
anti‐epileptic drugs.12,13,16,24 Significant improvements were observed
compared to placebo as an add‐on therapy. Within the other 3 clinical
trials of prospective open‐label design (n = 203), CBD was adminis-
tered at an average dosing of 42 mg/kg/d and significant improve-
ments in quality of life and seizure frequency compared to baseline
were observed.26-28 3 case series and 1 case report (total n = 16)
reported beneficial effects of CBD on seizure frequency, duration
and severity with an average administered dose of 21 mg/kg/d.33-36
Seven studies were conducted in the context of schizophrenia and
bipolar disorder. Within the RCTs, 2 conducted with an average dosing
MILLAR ET AL. 1897of 15 mg/kg/d over 4 or 8 weeks reported positive reductions in psy-
chotic or psychiatric symptoms and a better side effect profile
(n = 130).11,19 One of these compared CBD against an active control
(amisulpride), and the other as an add‐on therapy to usual medication
compared to placebo as an add‐on therapy. However, a third RCT
employing CBD as an add‐on therapy did not report any improve-
ments in cognition or symptoms of schizophrenia after a lower aver-
age dose of 10 mg/kg/d over 6 weeks (n = 36).14 An acute dose of
5 or 10 mg/kg/d did not improve selective attention in a placebo‐
controlled trial of 28 schizophrenia patients.30 A number of case
studies have also been conducted by Zuardi and colleagues in this
medical context. In 2 patients with bipolar disease, 20 mg/kg/d was
ineffective in treating manic episodes.39 CBD was similarly unable to
improve symptoms in 3 schizophrenia patients, although 1 patient
described mild improvement.41 Another case report described
improvement in psychiatric ratings following an average dose of
25 mg/kg/d over 4 weeks.40
Results are mixed within Parkinson's disease studies. Within an
RCT in 21 patients, 1.25 or 5 mg/kg/d CBD had no effect on motor
and general symptoms. However, the 5 mg/kg/d dose improved
well‐being and quality of life scores.18 The remaining studies are case
studies in which CBD decreased psychotic symptoms and Parkinson's
disease ratings (n = 6; 7 mg/kg/d),31 improved rapid eye movement
sleep behaviour disorder (n = 4; 1 mg/kg/d),37 decreased dyskinesia
with 2 to 3 mg/kg/d doses (n = 1), but exaggerated Parkinson's disease
symptoms with 5 and 7 mg/kg/d doses.42
CBD did not change therapeutic outcome variables in a double‐
blind RCT in Huntington disease patients compared to placebo
(n = 15; 10 mg/kg/d for 6 weeks),23 but improved dystonia disability
in an open pilot study (n = 5; 10 mg/kg/d for 6 weeks),32 and improved
spasm frequency and severity in a case report in 1 patient with Meige
syndrome (7 mg/kg/d).43
Within the RCTs, CBD did not significantly change the primary
outcomes in diabetes (n = 62), Crohn's disease (n = 19), ocular hyper-
tension (n = 6), chronic pain (mostly neuropathic; n = 24), or fatty liver
disease (n = 25).15,17,21,22,25 However, an average dose of 2.4 mg/kg/d
(range 0.3–13.3 mg/kg/d) was used in these studies, which is very low
in the clinical and clinical trial setting compared to other studies. Low
doses (10 mg/kg) did, however, produce positive responses in
generalised social anxiety disorder (SAD) in a double‐blind RCT in 24
patients.20 Likewise, in another double‐blind placebo‐controlled study,
a dose of 6.7 mg/kg reduced subjective anxiety in 10 adults with gen-
eralised SAD.5 Additionally, in a case report in a child, 0.6 mg/kg/d
increased sleep quality and duration, and decreased anxiety secondary
to PTSD.10
Lastly, it was found that doses of 5 mg/kg/d prevented occurrence
of graft‐vs‐host disease in a phase II clinical trial (n = 48) and
5–10 mg/kg/d doses have been shown in a case report to remove
withdrawal symptoms from a patient with cannabis dependency.29,38
Within studies that compared CBD against a placebo or control
(n = 17 publications), only 1 compared CBD against an active control
(and a greater clinical improvement and side effect profile was
observed with CBD against amisulpride), 8 compared CBD against aplacebo (monotherapy), and 8 studies compared CBD as an add‐on
therapy (adjunctive to antipsychotic medication, antiepileptic medica-
tion, anti‐Parkinson medication or pain medication) against placebo.
Analysis of these data revealed that a greater proportion of studies
reported a beneficial effect of CBD in the add‐on therapy group
compared to the monotherapy group (n = 6 and n = 2 respectively).
However, higher doses were used overall within the add‐on therapy
group compared to the monotherapy group (average 11 and
6 mg/kg/d, respectively) and, due to such a small data set and hetero-
geneity of studies, we did not perform any further analysis.4 | DISCUSSION
To our knowledge, this is the first study to compile and compare all
publications in which CBD was administered to clinical populations.
The aim of this systematic review was to better understand the range
of doses of CBD used in clinical studies. In total, 13 medical contexts
were included in this review amongst 35 studies including clinical trials
and case reports. A positive effect of CBD was reported in 66% of
studies, covering disorders including schizophrenia, SAD, epilepsy,
cannabis dependency and graft‐vs‐host disease, with doses ranging
between <1 and 50 mg/kg/d (i.e. <62–3100 mg/d for an adult).
Although we acknowledge that these results mix widely heteroge-
neous studies, it appears well founded to highlight the differences in
average dosing for positive effect studies against those without posi-
tive effects, which is confirmed when analysing studies per medical
context within each study design format. This suggests that CBD
potentially displays a wide therapeutic range, and variable minimum
doses are required for effect depending on primary outcomes
assessed and the population group. However, it is vital to note that
no conclusions can be drawn on the efficacy of CBD as larger phase
III and conclusive efficacy trials have not been conducted, with excep-
tion of epilepsy. A number of phase III clinical trials are registered on
clinicaltrials.gov, which should provide more evidence in the coming
years in the contexts of pain, anxiety, Crohn's disease, bipolar disorder,
Fragile X syndrome, epilepsy and more.
CBD is increasingly popular, both as a food and health supplement
and as a licensed medicine. Within this review, 51% of studies have
been published in the last 5 years (since 2013); however, the included
articles span over decades, with prominent publications first appearing
in the 1980s and early 1990s.24,40 Despite its long history of sole
administration to patients, there is surprisingly little published about
the pharmacokinetic properties of CBD, particularly its bioavailability,
making it difficult to estimate true effective doses.8 Historically, there
is a striking lack of dose‐ranging studies and, looking forward, there
are no registered trials on clinicaltrials.gov including specific dose‐
ranging investigations in their study design. Ideally, this review would
have compared plasma concentrations of CBD in order to more
accurately estimate therapeutic concentrations, but, due to the lack
of reporting, this was not possible.
Different effective plasma concentrations of CBD may be required
for achieving different endpoints across clinical populations, which is a
1898 MILLAR ET AL.recognised trait in a number of other drugs and diseases. For example,
aspirin (acetylsalicylic acid) is used at low doses for antiplatelet ther-
apy, and at higher doses as an analgesic agent.44,45 With CBD, lower
doses may be effective in anxiety relief, while higher doses may be
required for effective reduction in epileptic seizures. In studies where
there are good rationales for CBD use (e.g. Crohn's disease and
chronic pain46,47), neutral results may be secondary to subtherapeutic
dosing, and dose‐escalation trials with embedded pharmacokinetic
studies are the next logical step.15,22 Studies in this review using
higher doses concluded that CBD was generally well‐tolerated with
the most frequent side effects including drowsiness, nausea, somno-
lence, fatigue and vomiting.
Among the clinical trial records retrieved from clinicaltrials.gov,
only 60% of completed trials had results uploaded and available. This
may represent a significant publication bias and is suggestive of disre-
gard for the priority of publication of negative results, which is a well‐
recognised problem.48 Unfortunately, this may potentially skew the
findings presented in this review and so should be interpreted with
caution and is acknowledged as a limitation. We also acknowledge
that despite all routes of administration being oral, there may be fur-
ther bias introduced between studies as one dose cannot be directly
compared to another due to lack of standardisation of formulations
and pharmacokinetic activity, including differences in bioavailability
between an oral spray and an oral capsule.
Future studies should also consider the safety of drug interactions
with CBD. CBD is a known inhibitor of the cytochrome P450 (CYP)
system49 and can therefore increase plasma concentrations of medi-
cines already in use, in particular antiepileptic drugs. Indeed, this has
been reported in a number of publications investigating concomitant
use of CBD and antiepileptic drugs.50 Similarly, CYP inhibitors are
predicted to increase CBD plasma concentrations which should be
equally monitored. Where possible, further well designed trials with
CBD may disentangle whether CBD offers unique therapeutic poten-
tial in addition to benefits seen when used as an add‐on treatment.5 | CONCLUSION
Although larger confirmatory and efficacy clinical trials examining dos-
ing in more detail for each medical context is required, this review sum-
marises that CBD appears to offer a wide‐range of activity between 1
and 50 mg/kg/d, and there was a tendency of studies with positive
outcomes to have used higher doses of CBD. We recommend pharma-
cokinetic dosing schedules in subsequent trials to consider this range
along with safety data and individual patient requirements. Finally,
we implore all completed trial results to be made readily available so
the research community can progress and learn from equally important
positive and negative outcomes for the ultimate benefit of patients.
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